The data from these two studies will provide meaningful information related to our future clinical development of LB1148.” “Importantly, we remain on track for the Phase 2 topline data readout for the prevention of post-surgical abdominal adhesions in the coming weeks. Finley, Chief Executive Officer of Palisade Bio. “Achieving our enrollment target in this study is an important milestone for our LB1148 clinical program,” commented J.D. Carlsbad, CA, J(GLOBE NEWSWIRE) - Palisade Bio, Inc. ( Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the completion of patient enrollment in its dose optimization study of LB1148.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |